|

Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial

RECRUITINGN/ASponsored by ANRS, Emerging Infectious Diseases
Actively Recruiting
PhaseN/A
SponsorANRS, Emerging Infectious Diseases
Started2025-03-20
Est. completion2027-07-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06522256

Summary

HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and/or anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study;
* Informed and written signed consent
* Participant with regular health insurance

Exclusion Criteria:

* Participant under guardianship or curatorship
* Participant with free State medical assistance
* Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.

Conditions3

Anal CancerCancerHPV Infection

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.